CVS Group plc (LSE:CVSG) reported encouraging trading for the four months to October 2025, with group sales rising 5.7% and adjusted EBITDA up 6.2%. Membership in the company’s Healthy Pet Club continued to grow, while ongoing investment in practice refurbishments and digital technology strengthened its clinical infrastructure. CVS also made further progress in its Australian expansion, adding nine new practice sites, and is preparing for an upcoming transition to the main market of the London Stock Exchange. Despite challenges in the UK veterinary market, the company remains confident in its growth trajectory, supported by resilient demand for pet care and meaningful opportunities overseas.
The broader outlook for CVS is mixed: revenue trends are strong, but profitability pressures, short-term bearish technical signals, and valuation concerns temper near-term sentiment. Even so, recent corporate developments and strategic initiatives underpin a constructive long-term view.
More about CVS Group plc
CVS Group plc is a leading veterinary services provider with operations across the UK and Australia. Through a network of roughly 470 practices — including referral hospitals, out-of-hours centres, and a diagnostics laboratory division — the company delivers comprehensive clinical care. CVS also operates Animed Direct, an online pet pharmacy and retail platform. The group employs around 8,900 staff, including approximately 2,500 veterinary surgeons and 3,300 nurses and patient care assistants.
Leave a Reply